Do You Qualify for the Medicare GLP-1 Bridge? (2026 Guide)

If you're on Medicare and paying full price for a GLP-1 drug, you already know the math is brutal — we're talking over a thousand dollars a month.

The good news: as of July 1, 2026, a federal program called the Medicare GLP-1 Bridge brings that cost down to a flat $50 a month for eligible Part D members.

The catch? Only three products qualify, the formulation matters (Zepbound vials are excluded), and the program is temporary — it's scheduled to run through December 31, 2027.

In this guide, you'll learn exactly who qualifies, which drugs are included (and which are NOT), how the program actually works at the pharmacy, and what to do if you're not eligible.

What Is the Medicare GLP-1 Bridge?

For years, Medicare has had a hard rule: it doesn't cover GLP-1 drugs for weight loss.

Medicare covers GLP-1s for type 2 diabetes — that coverage has always been there. But if you wanted Wegovy or Zepbound strictly for obesity, Medicare said no.

The Medicare GLP-1 Bridge changes that — at least partially and temporarily.

It's a time-bound federal demonstration run directly by CMS (the agency that runs Medicare), scheduled to operate from July 1, 2026 through December 31, 2027. For eligible Part D members, it provides certain GLP-1 weight-loss drugs for a flat $50-per-month copay.

Here's the part almost everyone gets wrong:

The Bridge does not run through your Part D plan. CMS administers it outside the normal Part D benefit, using a single central processor that handles prior authorization, claims, and payment to pharmacies. Your plan doesn't opt in, doesn't adjudicate the claim, and can't say no to the Bridge — so you don't need to call your plan to ask whether it "participates." There is nothing for plans to participate in.

And because the Bridge sits outside Part D, the Part D deductible does not apply. The $50 is a flat copay from your first fill.

Which Drugs Are Covered — and Which Are NOT

This is where the Bridge is far narrower than most headlines suggest. Per CMS, only three products qualify:

• Foundayo (orforglipron, the oral daily pill) — all forms
• Wegovy (semaglutide) — both the weekly injection and the tablets
• Zepbound KwikPen (tirzepatide) — the KwikPen ONLY

And here's what is NOT covered — read this carefully:

• Zepbound single-dose vials and single-dose pens are NOT included. The ~$299/mo LillyDirect self-pay vials do not qualify for the Bridge — if you want Zepbound at the $50 Bridge price, the prescription must be for the KwikPen.
• Ozempic is NOT included. It's approved for type 2 diabetes, not weight loss. If you take it for diabetes, ordinary Part D coverage is the path — not the Bridge.
• Mounjaro is NOT included. Same story: it's the diabetes-indicated sibling of Zepbound, and it is not on the Bridge's drug list.

Verified against the official CMS Medicare GLP-1 Bridge pages, July 2026. Program details can change — always confirm current rules with CMS before acting.

Who Qualifies for the Medicare GLP-1 Bridge?

Two things have to line up — and neither of them is your plan's permission.

Layer 1: You Need Medicare Part D

Eligibility starts with being enrolled in Medicare Part D prescription drug coverage — either a stand-alone Part D plan alongside Original Medicare, or a Medicare Advantage plan that includes drug coverage. Which specific plan you're in doesn't matter for the Bridge, because the Bridge doesn't run through your plan.

Layer 2: Clinical Criteria

The Bridge covers these drugs when used to reduce excess body weight and maintain weight reduction, and prior authorization runs through the CMS central processor. Expect the standard clinical picture insurers use for GLP-1s:

• BMI ≥ 30 (obesity), OR
• BMI ≥ 27 (overweight) with at least one weight-related condition — such as hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease
• A prescriber who can attest to and document the criteria in your chart

Bottom line:

Part D enrollment + documented clinical eligibility + a prescription for a Bridge-eligible product. That's the whole gate. There is no "participating plan" requirement — that's a myth.

What About the Cardiovascular Indication for Wegovy?

Separate from the Bridge, Wegovy has an FDA indication to reduce cardiovascular risk in adults with established cardiovascular disease who also have obesity or overweight. That's a medical indication that can support ordinary Part D coverage — a different path from the Bridge entirely. If you have established cardiovascular disease, make sure your prescriber documents that indication specifically.

For a deeper look at how to frame coverage requests strategically, see our guide on what to do when insurance won't cover Wegovy for weight loss.

How the Bridge Works at the Pharmacy (Your Plan Isn't Involved)

Because CMS runs the Bridge outside the Part D benefit, the flow is simpler than people expect:

• Your prescriber writes a prescription for a Bridge-eligible product (Foundayo, Wegovy, or the Zepbound KwikPen) and handles the prior authorization through the CMS central processor
• You take it to the pharmacy like any other prescription
• The pharmacy bills the CMS central processor — not your Part D plan
• You pay the flat $50 copay

Here's a reality check:

The program launched July 1, 2026, and pharmacies and prescribers are still getting up to speed. If a pharmacy tells you "your plan doesn't cover this," that's the wrong frame — the claim doesn't go to your plan at all. Point them to the official CMS Medicare GLP-1 Bridge pharmacy guidance, or try a different pharmacy.

The Catch — Read This Before You Get Too Excited

We want to be straightforward with you here because this program is genuinely useful, but it comes with real limitations.

It's a Demonstration, Not a Permanent Benefit

The Medicare GLP-1 Bridge is scheduled to end December 31, 2027. Demonstration programs can be extended, expanded, or ended. What's $50/month today is not a guarantee of $50/month indefinitely.

If you start a GLP-1 medication under the Bridge, have a plan for what happens if the program ends. GLP-1 drugs generally need to be taken long-term to maintain results, so a coverage gap isn't just a financial inconvenience.

The Formulation Trap

Only the Zepbound KwikPen is covered — not the vials, and not the single-dose pens. And Ozempic and Mounjaro aren't in the program at all. Getting the prescription written for the right product is on you and your prescriber.

The Fine Print on the $50

The $50 copay is flat and predictable — the Part D deductible does not apply. But two things to know: the $50 does not count toward your Part D out-of-pocket total (TrOOP), and there is no Extra Help / Low-Income Subsidy discount on it — LIS beneficiaries pay the same $50.

Standard Medicare Still Excludes Weight-Loss GLP-1s

Outside the Bridge, Medicare's standard rule hasn't changed: GLP-1s for weight loss are not a covered benefit. The Bridge is a temporary, narrow exception — not a fix to that underlying policy gap.

What If You Don't Qualify for the Bridge?

If you don't have Part D, don't meet the clinical criteria, or want a drug the Bridge doesn't cover, don't stop here. There are still legitimate paths to lower costs.

Cash Self-Pay Programs (No Insurance Required)

Several manufacturers offer self-pay pricing that bypasses insurance entirely. As of mid-2026:

• Foundayo (orforglipron): $149/month self-pay for 1.5 mg and 4 mg doses (4 mg price holds through August 31, 2026, then moves to ~$199/month)
• Wegovy (injectable): ~$349/month for most doses ($399 for Wegovy HD) via the manufacturer program
• Wegovy Pill (oral): $149/month self-pay for 1.5 mg and 4 mg
• Zepbound: LillyDirect self-pay vials from ~$299/month for lower doses (higher doses cost more) — remember, these vials are a self-pay path only and are NOT eligible under the Bridge

These prices don't require insurance — but they have dose limits and expiration dates. Verify current pricing before you fill.

Is Diabetes or Cardiovascular Disease Documented?

GLP-1 coverage for type 2 diabetes is near-universal in Medicare Part D. If you have a diabetes diagnosis, your prescriber may be able to request coverage for Ozempic or Mounjaro through that indication — the ordinary Part D path, no Bridge needed.

Similarly, Wegovy's cardiovascular risk reduction indication is a covered medical use — not just a weight-loss request. If cardiovascular disease is in your chart, that framing changes the coverage conversation significantly.

For a full walkthrough of how to use these leverage points, read our guide on how to get Zepbound covered by insurance in 2026.

What If You're on Medicaid?

Medicaid GLP-1 coverage for weight loss varies by state. As of 2026, 13 states are confirmed to cover it, while California, Michigan, and Pennsylvania are confirmed to be cutting that coverage. Coverage for diabetes is available nearly everywhere. Check our Medicaid coverage guide for your state's current status.

If you're navigating a denial through any insurance path, our appeal guide walks you through the full ladder — from internal appeals to external review.

The takeaway here is simple:

The Medicare GLP-1 Bridge is a major step forward, but it's not the only step. Whether you qualify for the Bridge or not, there's almost always another path worth exploring — and you don't have to navigate it alone.

Your Next Move

The Medicare GLP-1 Bridge is the first real crack in Medicare's long-standing wall against weight-loss drug coverage — and for eligible Part D members, it cuts a $1,300+ monthly bill down to a flat $50.

The keys: confirm you have Part D, make sure your clinical documentation is tight, get the prescription written for a Bridge-eligible product (KwikPen, not vials, if it's Zepbound), and have a backup plan for when the demonstration ends after December 31, 2027.

Which product are you and your clinician considering — the Foundayo pill, Wegovy, or the Zepbound KwikPen? Use our navigator to compare your options now.